European Patent Office

T 2220/14 (VelocImmune mouse/REGENERON) of 09.11.2015

European Case Law Identifier
ECLI:EP:BA:2015:T222014.20151109
Date of decision
9 November 2015
Case number
T 2220/14
Petition for review of
-
Application number
02709544.7
IPC class
C12N 15/00
Language of proceedings
English
Distribution
Distributed to board chairmen (C)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
METHODS OF MODIFYING EUKARYOTIC CELLS
Applicant name
REGENERON PHARMACEUTICALS, INC.
Opponent name
Kymab Limited
Merus B.V.
Novo Nordisk A/S
Board
3.3.08
Headnote
-
Relevant legal provisions
European Patent Convention Art 123(2)European Patent Convention Art 123(3)European Patent Convention Art 54European Patent Convention Art 56European Patent Convention Art 83European Patent Convention Art 84Rules of procedure of the Boards of Appeal Art 12(4)Rules of procedure of the Boards of Appeal Art 13(1)Rules of procedure of the Boards of Appeal Art 13(3)
Keywords
Postponement of the oral proceedings - (no)
Admission of documents (139), (161), (169) to (172) and (175) - (no)
Admission of documents (156), (158) and (168) - (yes)
Reopening debate - (no)
Confidentiality of documents (169) to (172) - (yes)
Admission of main request filed at the oral proceedings - (yes)
Requirements of the EPC fulfilled - (yes)
Catchword
Sufficiency of disclosure - see sections 55 to 72
Citing cases
T 1596/16T 2015/20

Order

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The case is remitted to the department of first instance with the order to maintain the patent on the basis of claims 1-6 of the main request received during the oral proceedings on 9 November 2015 at 16:00 hours, and a description to be adapted.